

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Laekna, Inc.**

**來凱醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2105)**

**CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE, AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

The board (the “**Board**”) of directors (the “**Directors**”) of Laekna, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Tang Wing Shan Winza (“**Ms. TANG**”) has resigned as a joint company secretary of the Company (the “**Joint Company Secretary**”) and has ceased to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from 2 February 2024.

Ms. TANG has confirmed that she has no disagreement with the Board and that there are no other matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange. The Board further announces that Ms. Ho Wing Nga (“**Ms. HO**”) was appointed as the Joint Company Secretary, Authorised Representative, and the Process Agent, with effect from 2 February 2024. Mr. KE Chenyu (“**Mr. KE**”) will continue acting as the other Joint Company Secretary.

The biographical details of Ms. HO and Mr. KE are as follows:

Ms. HO has over 25 years of experience in corporate governance services. She obtained a master’s degree in corporate governance from the Hong Kong Polytechnic University. Ms. HO is a fellow of both the Hong Kong Chartered Governance Institute (the “**HKCGI**”) and The Chartered Governance Institute. She is also a holder of the practitioner’s endorsement of HKCGI and a member of The Hong Kong Institute of Directors.

Mr. KE was appointed as a joint company secretary of our Company in May 2022. Mr. KE joined our Group in August 2021 as our head of legal, responsible for overseeing legal, regulatory and compliance matters of our Company.

Prior to joining our Group, Mr. KE worked at Kaye Scholer LLP from August 2011 to July 2013. He served as an associate at Benesch, Friedlander, Coplan & Aronoff LLP from September 2013 to July 2014. From August 2015 to August 2021, he served as the legal general manager of Shanghai Fosun High Technology (Group) Co., Limited, a wholly-owned subsidiary of Fosun International Limited (a company listed on the Stock Exchange, stock code: 656), and was responsible for the legal and compliance in healthcare sector.

Mr. KE obtained his Bachelor's degree in law from East China University of Political Science and Law in China in July 2007. He obtained his Master's degree in law from Georgetown University Law Center in the United States in May 2015.

Reference is made to the waiver granted to the Company by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a three-year period starting from the date of the listing of the Company's on the Stock Exchange (i.e. 29 June 2023), on the condition that Ms. TANG (or any other suitably qualified person) is engaged as the Joint Company Secretary to assist Mr. KE and enable him to acquire relevant experience (as defined in Note 2 to Rule 3.28 of the Listing Rules), in order to discharge his duties under the position of Joint Company Secretary. Such waiver was revoked upon Ms. TANG's resignation on 2 February 2024. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a new waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules with respect to the eligibility of Mr. KE to act as a Joint Company Secretary (the "**New Waiver**") from 2 February 2024 (i.e. from the date on which Ms. HO was appointed as the other Joint Company Secretary) to 28 June 2026 (the "**New Waiver Period**"). The New Waiver is granted on the following conditions:

- (i) Mr. KE will be assisted by Ms. HO during the New Waiver Period;
- (ii) the New Waiver will be revoked if there are material breaches of the Listing Rules by the Company; and
- (iii) the Company will disclose details of the New Waiver, including reasons for the New Waiver and the conditions thereto, and the qualification and experience of both Ms. HO and Mr. KE, by way of an announcement.

Before the end of the New Waiver Period, the Company must notify the Stock Exchange, demonstrate and seek the Stock Exchange's confirmation that Mr. KE, having had the benefit of Ms. HO's assistance during the New Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The New Waiver applies to Ms. HO's appointment as the Joint Company Secretary only and will be revoked immediately if and when Ms. HO ceases to provide assistance to Mr. KE. The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes.

The Board wishes to take this opportunity to express its gratitude to Ms. TANG for her contribution during her tenure of service and also to extend a warm welcome to Ms. HO on her new appointment as the Joint Company Secretary, Authorised Representative, and the Process Agent.

By Order of the Board  
**Laekna, Inc.**  
**Dr. LU Chris Xiangyang**  
*Chairman*

Hong Kong, 2 February 2024

*As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling, and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei, and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.*